ESC 365 - Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

Back

ESC Premium Access

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

Session: PSCK9 inhibition: a new horizon in LDL-C management

Topic: Lipids

Speaker: Professor C. Cannon (Boston, US)

About the speaker

Professor Christopher Paul Cannon

Brigham and Women's Hospital, Boston (United States of America)

38 presentations

0 follower

6 more presentations in this session

LDL-C exposure and atherosclerosis progression.

Speaker: Professor A. Catapano (Milan, IT)

Access

PCSK9 inhibition: the data today and tomorrow.

Speaker: Professor S. Nicholls (Melbourne, AU)

Access

Learnings and clinical insights from SPIRE.

Speaker: Doctor P. Ridker (Boston, US)

Access

Guidelines: commonalities and discrepancies.

Speaker: Doctor J. Robinson (Iowa, US)

Access

Identifying appropriate patients to treat: a case-based approach.

Speaker: Professor C. Cannon (Boston, US) Professor A. Catapano (Milan, IT) Professor S. Nicholls (Melbourne, AU) Doctor P. Ridker (Boston, US) Doctor J. Robinson (Iowa, US)

Access

Access the full session

PSCK9 inhibition: a new horizon in LDL-C management

Speakers: Professor C. Cannon, Professor A. Catapano, Professor S. Nicholls, Doctor P. Ridker, Doctor J. Robinson...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

About the speaker

Professor Christopher Paul Cannon

6 more presentations in this session

LDL-C exposure and atherosclerosis progression.

PCSK9 inhibition: the data today and tomorrow.

Learnings and clinical insights from SPIRE.

Guidelines: commonalities and discrepancies.

Identifying appropriate patients to treat: a case-based approach.

Access the full session

PSCK9 inhibition: a new horizon in LDL-C management

About the event

ESC Congress 2017

ESC 365 is supported by